RT Journal Article
SR Electronic
T1 Clinical validity of expanded carrier screening: evaluating the gene-disease relationship in more than 200 conditions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.13.19014894
DO 10.1101/2019.12.13.19014894
A1 Marie Balzotti
A1 Linyan Meng
A1 Dale Muzzey
A1 Katherine Johansen Taber
A1 Kyle Beauchamp
A1 Myriad Genetics Curation Team
A1 Baylor Genetics Curation Team
A1 Rebecca Mar-Heyming
A1 Bethany Buckley
A1 Krista Moyer
YR 2019
UL http://medrxiv.org/content/early/2019/12/15/2019.12.13.19014894.abstract
AB Objective Clinical guidelines consider expanded carrier screening (ECS) to be an acceptable method of carrier screening. However, broader guideline support and payer adoption require evidence for associations between the genes on ECS panels and the conditions for which they aim to identify carriers. We applied a standardized framework for evaluation of gene-disease association to assess the clinical validity of conditions screened by ECS panels.Methods The ClinGen gene curation framework was used to assess genetic and experimental evidence of associations between 208 genes and conditions screened on two commercial ECS panels. Twenty-one conditions were previously classified by ClinGen, and the remaining 187 were evaluated by curation teams at two laboratories. To ensure consistent application of the framework across the laboratories, concordance was evaluated on a subset of conditions.Results All 208 evaluated conditions met the evidence threshold for supporting a gene-disease association. Furthermore, 203 of 208 (98%) achieved the strongest (“Definitive”) level of gene-disease association. All conditions evaluated by both commercial laboratories were similarly classified.Conclusion Assessment using the ClinGen standardized framework revealed strong evidence of gene-disease association for conditions on two ECS panels. This result establishes the disease-level clinical validity of the panels considered herein.Competing Interest StatementAll authors are current or former employees of Myriad Genetics, Myriad Women's Health, or Baylor Genetics.Funding StatementThis study was funded internally by Myriad Genetics.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll gene-disease associations have been submitted to ClinGen for public posting.